Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perturbing <i>O</i>-GlcNAcase Modulates the Expression and Distribution of Galectin-3.

Cells·2026
Same author

Cannabis and tobacco co-use predicts psychosis in clinical high risk cohorts.

Nature. Mental health·2026
Same author

Tobacco Use is Related to Parietal-Hippocampal Connectivity in People at Clinical High Risk for Psychosis.

medRxiv : the preprint server for health sciences·2026
Same author

Cannabis and Tobacco Co-Use Is Associated With Impaired Neurocognitive Performance in Individuals at Clinical High Risk for Psychosis.

Biological psychiatry. Cognitive neuroscience and neuroimaging·2026
Same author

A Novel Therapeutic Mechanism for Nicotine Craving in Schizophrenia.

medRxiv : the preprint server for health sciences·2026
Same author

Network-targeted TMS modulates nicotine craving and default mode network connectivity in psychotic disorders.

Brain stimulation·2026

Related Experiment Video

Updated: Mar 17, 2026

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.2K

Development of a model system for neuronal dysfunction in Fabry disease.

Christine R Kaneski1, Roscoe O Brady1, John A Hanover2

  • 1National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.

Molecular Genetics and Metabolism
|July 30, 2016
PubMed
Summary

Researchers developed a new in vitro model for Fabry disease, a genetic disorder affecting multiple systems. This model uses gene silencing to study neuronal dysfunction and neurotransmitter release, offering insights into the disease

Keywords:
AcetylcholineAlpha-galactosidase AFabry diseaseGene silencingNeuropathy

More Related Videos

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons
07:43

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons

Published on: January 7, 2019

7.4K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.4K

Related Experiment Videos

Last Updated: Mar 17, 2026

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

3.2K
Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons
07:43

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons

Published on: January 7, 2019

7.4K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.4K

Area of Science:

  • Biochemistry
  • Genetics
  • Neuroscience

Background:

  • Fabry disease is a genetic disorder caused by alpha-galactosidase A (AGA) deficiency, leading to glycosphingolipid accumulation.
  • It affects multiple organ systems, including the nervous system, causing neuropathic pain and autonomic dysfunction.
  • Understanding the precise mechanisms of neuronal dysfunction in Fabry disease is limited by a lack of suitable model systems.

Purpose of the Study:

  • To develop an in vitro model system for studying neuronal dysfunction in Fabry disease.
  • To investigate the impact of reduced alpha-galactosidase A activity on neuronal function, specifically neurotransmitter release.

Main Methods:

  • Utilized short-hairpin RNA (shRNA) to create a stable knock-down of alpha-galactosidase A (AGA) in the human cholinergic neuronal cell line LA-N-2.
  • Assessed AGA enzyme activity and globotriaosylceramide storage in gene-silenced cells.
  • Measured the release of the neurotransmitter acetylcholine from the modified neuronal cells.

Main Results:

  • The gene-silenced LA-N-2 cells exhibited significantly reduced AGA activity.
  • Accumulation of globotriaosylceramide was observed in the gene-silenced cells, consistent with Fabry disease pathology.
  • A significant reduction in acetylcholine release was detected in the neuronal cells with reduced AGA activity.

Conclusions:

  • The developed in vitro model effectively replicates key aspects of neuronal dysfunction seen in Fabry disease.
  • This model system demonstrates impaired neurotransmitter release, offering a valuable tool for further research into Fabry disease's neurological manifestations.
  • The findings highlight the potential of this model to elucidate the mechanisms underlying neuronal dysfunction in Fabry disease.